Skip to main content
Top
Published in: Breast Cancer Research and Treatment 2/2008

01-01-2008 | Preclinical Study

Correlation of levels and patterns of genomic instability with histological grading of invasive breast tumors

Authors: Rachel E. Ellsworth, Jeffrey A. Hooke, Brad Love, Jennifer L. Kane, Heather L. Patney, Darrell L. Ellsworth, Craig D. Shriver

Published in: Breast Cancer Research and Treatment | Issue 2/2008

Login to get access

Abstract

Pathological grade is a useful prognostic factor for stratifying breast cancer patients into favorable (well-differentiated tumors) and less favorable (poorly-differentiated tumors) outcome groups. The current system of tumor grading, however, is subjective and a large proportion of tumors are characterized as intermediate-grade tumors, making determination of optimal treatments difficult. To determine whether molecular profiles can discriminate breast disease by grade, patterns and levels of allelic imbalance (AI) at 26 chromosomal regions frequently altered in breast disease were examined in 185 laser microdissected specimens representing well-differentiated (grade 1; n = 55), moderately-differentiated (grade 2; n = 71), and poorly-differentiated (grade 3; n = 59) stage I–IV breast tumors. Overall levels of AI were significantly higher in grade 3 compared to grade 1 tumors (P < 0.05). Grades 1 and 3 showed distinct genetic profiles - grade 1 tumors were associated with large deletions of chromosome 16q22, while alterations at 9p21, 11q23, 13q14, 17p13.1 and 17q12 were characteristics of grade 3 carcinomas. In general, levels and patterns of AI in grade 2 carcinomas were intermediate between grade 1 and grade 3 tumors. Patterns of AI accurately categorized ∼70% of samples into high- or low-grade disease groups, suggesting that the majority of breast tumors have genetic profiles consistent with high- or low-grade, and that molecular signatures of breast tumors can be useful for more accurate characterization of invasive breast cancer.
Literature
1.
go back to reference Millis RR et al (1998) Tumor grade does not change between primary and recurrent mammary carcinoma. Eur J Cancer 34:548–553PubMedCrossRef Millis RR et al (1998) Tumor grade does not change between primary and recurrent mammary carcinoma. Eur J Cancer 34:548–553PubMedCrossRef
2.
go back to reference Roylance R et al (2002) Allelic imbalance analysis of chromosome 16q shows that grade I and grade III invasive ductal breast cancers follow different genetic pathways. J Pathol 196:32–36PubMedCrossRef Roylance R et al (2002) Allelic imbalance analysis of chromosome 16q shows that grade I and grade III invasive ductal breast cancers follow different genetic pathways. J Pathol 196:32–36PubMedCrossRef
3.
go back to reference Roylance R et al (1999) Comparative genomic hybridization of breast tumors stratified by histological grade reveals new insights into the biological progression of breast cancer. Cancer Res 59:1433–1436PubMed Roylance R et al (1999) Comparative genomic hybridization of breast tumors stratified by histological grade reveals new insights into the biological progression of breast cancer. Cancer Res 59:1433–1436PubMed
4.
go back to reference Buerger H et al (2001) Ductal invasive G2 and G3 carcinomas of the breast are the end stages of at least two different lines of genetic evolution. J Pathol 194(2):165–170PubMedCrossRef Buerger H et al (2001) Ductal invasive G2 and G3 carcinomas of the breast are the end stages of at least two different lines of genetic evolution. J Pathol 194(2):165–170PubMedCrossRef
5.
go back to reference Sotiriou C et al (2006) Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98(4):262–272PubMedCrossRef Sotiriou C et al (2006) Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98(4):262–272PubMedCrossRef
6.
go back to reference Henson DE et al (1991) Relationship among outcome, stage of disease, and histologic grade for 22,616 cases of breast cancer. Cancer 68(10):2142–2149PubMedCrossRef Henson DE et al (1991) Relationship among outcome, stage of disease, and histologic grade for 22,616 cases of breast cancer. Cancer 68(10):2142–2149PubMedCrossRef
7.
go back to reference Elston CW, Ellis IO (1998) Systemic pathology 3E. In: Elston CW, Ellis IO (eds) The breast. Churchill Livingstone, Edinburgh pp. 3–10 Elston CW, Ellis IO (1998) Systemic pathology 3E. In: Elston CW, Ellis IO (eds) The breast. Churchill Livingstone, Edinburgh pp. 3–10
8.
go back to reference American Joint Committee on Cancer. 2002. AJCC Cancer Staging Manual. 6 ed. Greene FL et al (eds). New York: Springer American Joint Committee on Cancer. 2002. AJCC Cancer Staging Manual. 6 ed. Greene FL et al (eds). New York: Springer
9.
go back to reference Bloom HJ, Richardson WW (1957) Histological grading and prognosis in breast cancer. Br J Cancer 11:359–377PubMed Bloom HJ, Richardson WW (1957) Histological grading and prognosis in breast cancer. Br J Cancer 11:359–377PubMed
10.
go back to reference Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow up. Histopathology 19:403–410PubMedCrossRef Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow up. Histopathology 19:403–410PubMedCrossRef
11.
go back to reference Ellsworth DL et al (2003a) Laser capture microdissection of paraffin-embedded tissues. Biotechniques 34(1):42–46 Ellsworth DL et al (2003a) Laser capture microdissection of paraffin-embedded tissues. Biotechniques 34(1):42–46
12.
go back to reference Ellsworth RE et al (2003b) High-throughput loss of heterozygosity mapping in 26 commonly deleted regions in breast cancer. Cancer Epidemiol Biomarkers Prev 12(9):915–919 Ellsworth RE et al (2003b) High-throughput loss of heterozygosity mapping in 26 commonly deleted regions in breast cancer. Cancer Epidemiol Biomarkers Prev 12(9):915–919
13.
go back to reference Medintz IL et al (2000) Loss of heterozygosity assay for molecular detection of cancer using energy-transfer primers and capillary array electrophoresis. Genome Res 10:1211–1218PubMedCrossRef Medintz IL et al (2000) Loss of heterozygosity assay for molecular detection of cancer using energy-transfer primers and capillary array electrophoresis. Genome Res 10:1211–1218PubMedCrossRef
14.
go back to reference Ellsworth RE et al (2005) Allelic imbalance in primary breast carcinomas and metastatic tumors of the axillary lymph nodes. Mol Cancer Res 3:71–77PubMedCrossRef Ellsworth RE et al (2005) Allelic imbalance in primary breast carcinomas and metastatic tumors of the axillary lymph nodes. Mol Cancer Res 3:71–77PubMedCrossRef
15.
16.
go back to reference Cleton-Jansen AM et al (2004) Different mechanisms of chromosome 16 loss of heterozygosity in well- versus poorly differentiated ductal breast cancer. Genes Chromosomes Cancer 41:109–116PubMedCrossRef Cleton-Jansen AM et al (2004) Different mechanisms of chromosome 16 loss of heterozygosity in well- versus poorly differentiated ductal breast cancer. Genes Chromosomes Cancer 41:109–116PubMedCrossRef
17.
go back to reference Bieche I, Lidreau R (2000) Loss of heterozygosity at 13q14 correlates with RB1 gene underexpression in human breast cancer. Mol Carcinog 29(3):151–158PubMedCrossRef Bieche I, Lidreau R (2000) Loss of heterozygosity at 13q14 correlates with RB1 gene underexpression in human breast cancer. Mol Carcinog 29(3):151–158PubMedCrossRef
18.
go back to reference Lukas J et al (1995) Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature 375:503–506PubMedCrossRef Lukas J et al (1995) Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature 375:503–506PubMedCrossRef
19.
go back to reference Seitz S et al (2001) Detailed deletion mapping in sporadic breast cancer at chromosomal region 17p13 distal to the TP53 gene: association with clinicopathological parameters. J Pathol 194:318–326PubMedCrossRef Seitz S et al (2001) Detailed deletion mapping in sporadic breast cancer at chromosomal region 17p13 distal to the TP53 gene: association with clinicopathological parameters. J Pathol 194:318–326PubMedCrossRef
20.
go back to reference Winqvist R et al (1995) Loss of heterozygosity for chromosome 11 in primary human breast tumors is associated with poor survival after metastasis. Cancer Res 55(12):2660–2664PubMed Winqvist R et al (1995) Loss of heterozygosity for chromosome 11 in primary human breast tumors is associated with poor survival after metastasis. Cancer Res 55(12):2660–2664PubMed
Metadata
Title
Correlation of levels and patterns of genomic instability with histological grading of invasive breast tumors
Authors
Rachel E. Ellsworth
Jeffrey A. Hooke
Brad Love
Jennifer L. Kane
Heather L. Patney
Darrell L. Ellsworth
Craig D. Shriver
Publication date
01-01-2008
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2008
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-007-9547-2

Other articles of this Issue 2/2008

Breast Cancer Research and Treatment 2/2008 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine